AbbVie said on Thursday its drug met the main goal in a late-stage trial in patients with early Parkinson's disease.

Investors who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to ...

AbbVie (ABBV) said its Phase 3 trial TEMPO-1 for experimental therapy Tavapadon reached main goal in Parkinson's disease.

Leerink Partners analyst David Risinger has maintained their neutral stance on ABBV stock, giving a Hold rating on September 13. David ...

The Phase III TEMPO-1 trial enrolled 529 adults aged between 40 and 80 years, diagnosed with Parkinson’s for less than three ...

AbbVie plans to share results from another phase 3 trial of tavapadon later this year, the pharma said in the release. That ...

Results from TEMPO-1, which showed that tavapadon significantly improved motor symptoms in patients with Parkinson’s disease, ...

AbbVie reported Thursday that its experimental Parkinson’s drug that it got from Cerevel Therapeutics helped alleviate ...

These results back up results from the TEMPO-3 trial, which tested tavapadon as an add-on therapy to levodopa and which also ...

The Phase III TEMPO-1 trial enrolled 529 adults, between the ages of 40 and 80, diagnosed with Parkinson’s for less than three years.

Drugmaker AbbVie (ABBV) announced Thursday positive topline results from its pivotal Phase 3 TEMPO-1 trial for tavapadon as a ...

AbbVie (NYSE:ABBV) announced Thursday its experimental therapy Tavapadon for Parkinson's disease reached the primary endpoint in a Phase 3 trial, indicating a statistically significant improvement ...